文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

自然杀伤 T 细胞独立于肿瘤特异性细胞毒性 T 细胞控制小鼠自发性癌。

iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells.

机构信息

Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto Scientifico San Raffaele, Milan, Italy.

出版信息

PLoS One. 2010 Jan 13;5(1):e8646. doi: 10.1371/journal.pone.0008646.


DOI:10.1371/journal.pone.0008646
PMID:20072624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2800182/
Abstract

BACKGROUND: CD1d-restricted invariant NKT (iNKT) cells are a subset of T lymphocytes endowed with innate effector functions that aid in the establishment of adaptive T and B cell immune responses. iNKT cells have been shown to play a spontaneous protective role against experimental tumors. Yet, the interplay between iNKT and tumor-specific T cells in cancer immune surveillance/editing has never been addressed. The transgenic adenocarcinoma of the mouse prostate (TRAMP) is a realistic model of spontaneous oncogenesis, in which the tumor-specific cytotoxic T cell (CTL) response undergoes full tolerance upon disease progression. PRINCIPAL FINDINGS: We report here that lack of iNKT cells in TRAMP mice resulted in the appearance of more precocious and aggressive tumors that significantly reduced animal survival. TRAMP mice bearing or lacking iNKT cells responded similarly to a tumor-specific vaccination and developed tolerance to a tumor-associated antigen at comparable rate. CONCLUSIONS: Hence, our data argue for a critical role of iNKT cells in the immune surveillance of carcinoma that is independent of tumor-specific CTL.

摘要

背景:CD1d 限制性不变自然杀伤 T(iNKT)细胞是一群具有先天效应功能的 T 淋巴细胞亚群,有助于建立适应性 T 和 B 细胞免疫反应。iNKT 细胞已被证明在实验性肿瘤中发挥自发的保护作用。然而,iNKT 细胞与肿瘤特异性 T 细胞在癌症免疫监视/编辑中的相互作用尚未得到解决。小鼠前列腺腺癌(TRAMP)是自发发生肿瘤的现实模型,其中肿瘤特异性细胞毒性 T 细胞(CTL)反应在疾病进展时会完全耐受。 主要发现:我们在这里报告,TRAMP 小鼠中缺乏 iNKT 细胞会导致更早熟和侵袭性肿瘤的出现,这显著降低了动物的存活率。携带或缺乏 iNKT 细胞的 TRAMP 小鼠对肿瘤特异性疫苗有类似的反应,并以相似的速度对肿瘤相关抗原产生耐受。 结论:因此,我们的数据表明,iNKT 细胞在对癌的免疫监视中起着关键作用,而与肿瘤特异性 CTL 无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ed/2800182/ac2ddf911b12/pone.0008646.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ed/2800182/ab4b7bb0a904/pone.0008646.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ed/2800182/123ef53b8cb5/pone.0008646.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ed/2800182/c458cbce4381/pone.0008646.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ed/2800182/f0e69cdcc03e/pone.0008646.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ed/2800182/ac2ddf911b12/pone.0008646.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ed/2800182/ab4b7bb0a904/pone.0008646.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ed/2800182/123ef53b8cb5/pone.0008646.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ed/2800182/c458cbce4381/pone.0008646.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ed/2800182/f0e69cdcc03e/pone.0008646.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ed/2800182/ac2ddf911b12/pone.0008646.g005.jpg

相似文献

[1]
iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells.

PLoS One. 2010-1-13

[2]
Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.

PLoS One. 2010-6-25

[3]
Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.

Prostate. 2008-5-15

[4]
Invariant NKT cells facilitate cytotoxic T-cell activation via direct recognition of CD1d on T cells.

Exp Mol Med. 2019-10-25

[5]
CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.

Immunol Cell Biol. 2011-11-1

[6]
Invariant NKT cells: regulation and function during viral infection.

PLoS Pathog. 2012-8-16

[7]
CD1d-unrestricted NKT cells are endowed with a hybrid function far superior than that of iNKT cells.

Proc Natl Acad Sci U S A. 2014-9-2

[8]
Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.

Eur J Immunol. 2005-1

[9]
Critical role for CD1d-restricted invariant NKT cells in stimulating intrahepatic CD8 T-cell responses to liver antigen.

Gastroenterology. 2008-6

[10]
Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells.

Proc Natl Acad Sci U S A. 2013-2-4

引用本文的文献

[1]
T Cell Receptor-Engaging Monoclonal Antibodies Mobilize the Anti-Tumor Functions of Invariant Natural Killer T Cells.

Crit Rev Oncog. 2024

[2]
The causality between CD8NKT cells and CD16CD56 on NK cells with hepatocellular carcinoma: a Mendelian randomization study.

Infect Agent Cancer. 2024-1-20

[3]
The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors.

Explor Target Antitumor Ther. 2022

[4]
Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.

Front Med (Lausanne). 2022-5-9

[5]
Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model.

Cancer Immunol Immunother. 2022-12

[6]
Targeting Sphingolipids for Cancer Therapy.

Front Oncol. 2021-10-19

[7]
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead.

Cancers (Basel). 2021-10-15

[8]
Human intestinal and circulating invariant natural killer T cells are cytotoxic against colorectal cancer cells via the perforin-granzyme pathway.

Mol Oncol. 2021-12

[9]
The Role of NKT Cells in Glioblastoma.

Cells. 2021-6-30

[10]
Invariant natural killer T cells balance B cell immunity.

Immunol Rev. 2021-1

本文引用的文献

[1]
Dicer-dependent microRNA pathway controls invariant NKT cell development.

J Immunol. 2009-8-15

[2]
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.

J Clin Invest. 2009-6

[3]
Type I natural killer T cells suppress tumors caused by p53 loss in mice.

Blood. 2009-6-18

[4]
Harnessing invariant NKT cells in vaccination strategies.

Nat Rev Immunol. 2009-1

[5]
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans.

J Clin Invest. 2008-12

[6]
Immune therapy for cancer.

Annu Rev Immunol. 2009

[7]
NKT-cell help to B lymphocytes can occur independently of cognate interaction.

Blood. 2009-1-8

[8]
Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.

Prostate. 2008-7-1

[9]
Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.

Blood. 2008-6-15

[10]
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.

Immunol Rev. 2008-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索